Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 InflammationGlobeNewsWire • 02/23/24
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority ReviewGlobeNewsWire • 02/21/24
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)GlobeNewsWire • 02/16/24
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)GlobeNewsWire • 02/16/24
Regeneron Pharmaceuticals, Inc. (REGN) Oppenheimer 34th Annual Healthcare Life Sciences Conference (Transcript)Seeking Alpha • 02/14/24
Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024Seeking Alpha • 02/10/24
The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record HighInvestors Business Daily • 02/02/24
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating ResultsGlobeNewsWire • 02/02/24
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 02/02/24
Gear Up for Regeneron (REGN) Q4 Earnings: Wall Street Estimates for Key MetricsZacks Investment Research • 01/30/24
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical ProgramsGlobeNewsWire • 01/30/24
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)GlobeNewsWire • 01/25/24
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)GlobeNewsWire • 01/25/24